Literature DB >> 16460008

Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer.

Yuichiro Higashimoto1, Yuya Asanomi, Satoru Takakusagi, Marc S Lewis, Kohei Uosaki, Stewart R Durell, Carl W Anderson, Ettore Appella, Kazuyasu Sakaguchi.   

Abstract

The p53 tumor suppressor is a tetrameric transcriptional enhancer, and its activity is compromised by mutations that cause amino acid substitutions in its tetramerization domain. Here we analyze the biochemical and biophysical properties of peptides corresponding to amino acids 319-358 of wild-type human p53, which includes the tetramerization domain, and that of a cancer-derived mutant with valine substituted for glycine 334. Unlike the wild-type peptide, the G334V peptide forms amyloid fibrils by a two-step process under physiological conditions of temperature and pH. Nevertheless, the G334V peptide is capable of forming heterooligomers with a wild-type peptide. Computational modeling of the G334V peptide structure suggests that substitution of valine for glycine 334 causes a local distortion that contributes to a beta-dominated structural transition leading to amyloid formation. Since the distortion is mostly on the surface, the mutant peptide is still able to form a pseudonative tetramer complex at higher concentrations and/or lower temperatures. Our study suggests a new potential mechanism by which mutations that compromise tetramer formation inactivate p53 as a tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460008      PMCID: PMC2536691          DOI: 10.1021/bi051192j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  58 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Assembly of amyloid protofibrils via critical oligomers--a novel pathway of amyloid formation.

Authors:  A J Modler; K Gast; G Lutsch; G Damaschun
Journal:  J Mol Biol       Date:  2003-01-03       Impact factor: 5.469

Review 3.  Protein folding and misfolding.

Authors:  Christopher M Dobson
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 4.  Amyloid fibrils from the viewpoint of protein folding.

Authors:  S Ohnishi; K Takano
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

5.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

Authors:  M K Lawless; S Barney; K I Guthrie; T B Bucy; S R Petteway; G Merutka
Journal:  Biochemistry       Date:  1996-10-22       Impact factor: 3.162

6.  Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Authors:  T Fujita; M Kiyama; Y Tomizawa; T Kohno; J Yokota
Journal:  Int J Oncol       Date:  1999-11       Impact factor: 5.650

7.  Solution structure of the tetrameric minimum transforming domain of p53.

Authors:  W Lee; T S Harvey; Y Yin; P Yau; D Litchfield; C H Arrowsmith
Journal:  Nat Struct Biol       Date:  1994-12

8.  A self-consistent method for the analysis of protein secondary structure from circular dichroism.

Authors:  N Sreerama; R W Woody
Journal:  Anal Biochem       Date:  1993-02-15       Impact factor: 3.365

9.  Detecting hidden sequence propensity for amyloid fibril formation.

Authors:  Sukjoon Yoon; William J Welsh
Journal:  Protein Sci       Date:  2004-08       Impact factor: 6.725

10.  Refined solution structure of the oligomerization domain of the tumour suppressor p53.

Authors:  G M Clore; J Ernst; R Clubb; J G Omichinski; W M Kennedy; K Sakaguchi; E Appella; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1995-04
View more
  28 in total

1.  Analysis of chameleon sequences by energy decomposition on a pairwise per-residue basis.

Authors:  Sukjoon Yoon; Heeyoung Jung
Journal:  Protein J       Date:  2006-07       Impact factor: 2.371

2.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

3.  p53 protein aggregation promotes platinum resistance in ovarian cancer.

Authors:  Y Yang-Hartwich; M G Soteras; Z P Lin; J Holmberg; N Sumi; V Craveiro; M Liang; E Romanoff; J Bingham; F Garofalo; A Alvero; G Mor
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  Rab-like protein 1 A is upregulated by cisplatin treatment and partially inhibits chemoresistance by regulating p53 activity.

Authors:  Changjin Chen; Ziyi Zhao; Shiyun Tang; Cuiwei Zhang
Journal:  Oncol Lett       Date:  2018-07-24       Impact factor: 2.967

5.  Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.

Authors:  Jiangtao Lei; Ruxi Qi; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  Phys Chem Chem Phys       Date:  2016-03-21       Impact factor: 3.676

Review 6.  Potential roles for prions and protein-only inheritance in cancer.

Authors:  H Antony; A P Wiegmans; M Q Wei; Y O Chernoff; K K Khanna; A L Munn
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

7.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

8.  A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers.

Authors:  Jacquelyn Powers; Emilia M Pinto; Thibaut Barnoud; Jessica C Leung; Tetyana Martynyuk; Andrew V Kossenkov; Aaron H Philips; Heena Desai; Ryan Hausler; Gregory Kelly; Anh N Le; Marilyn M Li; Suzanne P MacFarland; Louise C Pyle; Kristin Zelley; Katherine L Nathanson; Susan M Domchek; Thomas P Slavin; Jeffrey N Weitzel; Jill E Stopfer; Judy E Garber; Vijai Joseph; Kenneth Offit; Jill S Dolinsky; Stephanie Gutierrez; Kelly McGoldrick; Fergus J Couch; Brooke Levin; Morris C Edelman; Carolyn Fein Levy; Sheri L Spunt; Richard W Kriwacki; Gerard P Zambetti; Raul C Ribeiro; Maureen E Murphy; Kara N Maxwell
Journal:  Cancer Res       Date:  2020-07-16       Impact factor: 12.701

Review 9.  Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins.

Authors:  Jerson L Silva; Tuane C R G Vieira; Mariana P B Gomes; Ana Paula Ano Bom; Luis Mauricio T R Lima; Monica S Freitas; Daniella Ishimaru; Yraima Cordeiro; Debora Foguel
Journal:  Acc Chem Res       Date:  2010-02-16       Impact factor: 22.384

10.  NetCSSP: web application for predicting chameleon sequences and amyloid fibril formation.

Authors:  Changsik Kim; Jiwon Choi; Seong Joon Lee; William J Welsh; Sukjoon Yoon
Journal:  Nucleic Acids Res       Date:  2009-05-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.